Harrow

Harrow, Inc. is an eyecare pharmaceutical company based in Nashville, Tennessee, founded in 1998. The company specializes in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. Harrow operates through segments that include branded FDA-approved ophthalmology products and its ImprimisRx compounding business, employing 382 people under CEO Mark Baum. Harrow provides accessible and affordable prescription and non-prescription ophthalmic products, including compounded medications and branded therapeutics. Its portfolio features a range of solutions for eye conditions, such as inflammation, infection, and pain management. Notable products include IHEEZO, IOPIDINE, VEVYE, ZERVIATE, and MAXITROL, among others. The company has strengthened its market position through strategic acquisitions, including five products from Novartis, enhancing its offerings in the ophthalmic sector.